Payment overview · 2025
General Payments
$270.30
14 reported records · 8 companies
Healthcare provider profile · identity verified
Melissa C Gray, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ATHENS, AL · NPI 1215298849
Verified facts
What the public records show
CMS Open Payments records show Melissa C Gray, M.D. received $270.30 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.88 | 33.6% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.03 | 14.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.78 | 12.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.52 | 12.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.75 | 9.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.16 | 6.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.60 | 5.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.58 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $270.30 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 127 |
| Gabapentin | Gabapentin | 382 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 116 |
| Omeprazole | Omeprazole | 300 | 96 |
| Lisinopril | Lisinopril | 275 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 263 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 260 | 40 |
| Alprazolam | Alprazolam | 259 | 47 |
| Losartan Potassium | Losartan Potassium | 244 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 81 |
| Metformin Hcl | Metformin Hcl | 223 | 80 |
| Fluoxetine Hcl | Fluoxetine Hcl | 206 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 67 |
| Mounjaro | Tirzepatide | 189 | 39 |
| Tramadol Hcl | Tramadol Hcl | 180 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 59 |
| Clonazepam | Clonazepam | 155 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 22 |
| Furosemide | Furosemide | 132 | 49 |
| Ozempic | Semaglutide | 127 | 44 |
| Famotidine | Famotidine | 125 | 44 |
| Lorazepam | Lorazepam | 125 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 47 |
| Simvastatin | Simvastatin | 100 | 33 |
| Temazepam | Temazepam | 99 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | 27 |
| Carvedilol | Carvedilol | 90 | 30 |
| Trazodone Hcl | Trazodone Hcl | 89 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 66 | 14 |
| Eliquis | Apixaban | 64 | 18 |
| Atenolol | Atenolol | 63 | 19 |
| Montelukast Sodium | Montelukast Sodium | 63 | 24 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 18 |
| Meloxicam | Meloxicam | 61 | 24 |
| Potassium Chloride | Potassium Chloride | 59 | 21 |
| Allopurinol | Allopurinol | 57 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 16 |
| Eszopiclone | Eszopiclone | 50 | 14 |
| Fluconazole | Fluconazole | 50 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 28 |
| Estradiol | Estradiol | 47 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 14 |
| Spironolactone | Spironolactone | 46 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 12 |
| Ondansetron Odt | Ondansetron | 45 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 38 | 16 |
| Metformin Hcl Er | Metformin Hcl | 38 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 15 |
| Glipizide | Glipizide | 35 | 12 |
| Linzess | Linaclotide | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | 11 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nystatin | Nystatin | 26 | 18 |
| Diazepam | Diazepam | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | 12 |
| Baclofen | Baclofen | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 14 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $270.30 · 14 records | Novo Nordisk Inc | CONTRAVE, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Ozempic, QULIPTA, REXULTI, TRULANCE, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error